LcProt: Proteomics Longitudinal Cohort Study on Lung Cancer

Launched by THE FIRST AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIVERSITY · Jan 12, 2025

Keywords

ClinConnect Summary

The LcProt study is a clinical trial focused on understanding lung cancer better through a method called proteomics, which looks at proteins in the body. Researchers will collect tissue and blood samples from participants at important points during their treatment, such as before surgery and after starting medication, to help improve diagnosis and treatment options for lung cancer, particularly non-small cell lung cancer (NSCLC).

To participate in this study, individuals must be between 18 and 75 years old and have lung nodules confirmed by a CT scan. They should also be able to cooperate with preoperative tests and have good lung function. Participants will need to sign a consent form agreeing to take part in the study. If eligible, individuals can expect to provide samples at different times throughout their treatment, and their involvement will contribute to important research that could help future patients with lung cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Signing of the informed consent form;
• • 2. Male or female, aged 18-75 years;
• • 3. Patients with lung nodules confirmed by CT examination;
• • 4. Good preoperative pulmonary function cooperation and complete reporting;
• • 5. Preoperative chest single/dual phase CT scans without significant artefacts and with complete imaging;
• • 6. The interval between preoperative pulmonary function and single/dual phase CT scans does not exceed one month.
• Exclusion Criteria:
• • 1. Poor preoperative pulmonary function cooperation or missing reports;
• • 2. Preoperative chest single/dual phase CT scans exhibit significant artefacts or image omission;
• • 3. The interval between preoperative pulmonary function and single/dual phase CT scans exceeds one month;
• • 4. Complication with severe respiratory disorders (such as lung transplantation, pneumothorax, giant bullae, etc.);
• • 5. Coexisting with other severe functional impairments;
• • 6. Patients with obstructive lesions such as airway or esophageal stenosis;
• • (8) Medication use before pulmonary function testing that does not meet the cessation guidelines; (9) Pulmonary function report quality graded D-F.